Summary
Allometric principles have been applied to scale and predict human pharmacokinetic parameters of irbesartan, an important AT1 receptor antagonist. The preclinical data gathered from rats, macaques (monkeys) and dogs were used in the allometric analysis. The use of these species was rationalized because preclinical models based on these species have been used in the evaluation pharmacodynamic activity of irbesartan. The human parameter values for clearance (CL/F), volume of distribution (V/F), and elimination rate constant (Kel) were scaled using simple allometry (CL/F, V/F and Kel) or with correction factors (CL/F). The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted=9 h; observed=10–20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted=456 L; observed=260 L). The present work presents an opportunity for prospective allometric scaling for the compounds belonging to this important therapeutic class.
References
Cazaubon C., Gougat J., Bousquet F., Guiraudou P., Lacour C., Roccon A., Galindo G., Barthelemy G., Guatret B., Bernhardt C., Perreaut P., Breliere J-C., Le Fur G., Nisato D. (1993): Pharmacological characterization of SR 47436, a new nonpeptide AT1 angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther., 265, 826–834.
Locour R., Canals F., Galindo G., Cazaubon C., Segondy D., Nisato D. (1993): Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive models. Eur. J. Pharmacol., 264, 307–316.
Locour R., Roccon A., Cazaubon C., Segondy D., Nisato D. (1993): Pharmacological study of SR 47436, a non-peptide angiotensin II AT1 angiotensin receptor anatagonist, in conscious monkeys. J. Hypertens., 11, 1187–1194.
Roccon A., Marchionni D., Donat F., Segondy D., Cazaubon C., Nisato D. (1994): A pharmacological study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br. J. Pharmacol., 111, 145–150.
Davi H., Tronquet G., Miscoria L., Perrier P., Dupont J., Caix J., Simland J., Berger Y. (2000): Disposition of irbesartan, an angiotensin H AT1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metabol. Dispos., 28, 79–88.
Wood J.M., Gulati N., Forgiarini P., Fuhrer W., Hofbauer K.G. (1985): Effects of a specific and long-acting rennin inhibitor in the marmoset. Hyperten., 7, 797–803.
Michel J.B., Wood J., Hofbauer K.G., Corvol P., Menard J. (1984): Blood pressure effects of rennin inhibitors by human renis antiserum in normotensive marmosets. Am. J. Phsiol., 246, 309–316.
DeGraaf G.L., Pals D.T., Cough S.J., Lawson J.A. (1993): Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in honhuman primates. J. Pharmacol. Exp. Ther., 263, 6–10.
Huang X.H., Qiu F.R., Xie H.T., Li J. (2005): Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorthiazide in renal hypertensive dogs. J. Cardiovasc. Pharmacol., 46, 863–869.
Chando T.J., Evertt D.W., Kahle A.D., Starrett A.M., Vachharajani N., Shyu W.C., Kripalani K.J., Barbhaiya R.H. (1998): Biotransformation of irbesartan in man. Drug Metabol. Dispos., 26, 408–417.
Vachharajani N.N., Shyu W.C., Chando T.J., Everett D.W., Greene D.S., Barbhaiya R.H. (1998): Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J. Clin. Pharmacol., 38, 702–707.
Marino M.R., Langenbacher K.M., Raymond R.H., Ford N.F., Lasseter K.C. (1998): Pharmacokinetics and pharmacodynamics of Irbesertan in patients with hepatic cirrhosis. J. Clin. Pharmacol., 38, 345–356.
Webrer B. (2000): A review of clinical experience with the Angiotensin II receptor antagonist Irbesertan, Cardiovasc. Drug Rev., 18, 103–126.
Mahmood I., Balian J.D. (1996): Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci., 85, 411–414.
Mahmood I., Sahawalla C. (2002): Interspecies scaling of biliary excreted drugs. J. Pharm. Sci., 91, 1908–1914.
Ahlawat P., Srinivas N.R. (2008): Allometric prediction of the human pharmacokinetic parameters for naveglitazar. Eur. J. Drug Metabol. Pharmacokinet., 3, 187–190.
Ahlawat P., Srinivas N.R. (2009): Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data. Xenobiotica, 38, 1377–1385.
Boxembaun H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokin. Biopharmacol., 10, 201–227.
Mahmood I. (2005): Interspecies scaling of biliary excreted drugs: a comparison of several methods. J. Pharm. Sci., 94, 883–892.
Pavan Kumar V.V., Vinu C.A., Mullangi R., Srinivas N.R. (2007): Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. Eur. J. Drug Metabol. Pharmacokinet., 32, 29–37.
Perrier L., Bourrie M., Martil E., Tronquet C., Masse D., Berger Y., Magdalou J., Fabre G. (1994): In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J. Pharmacol. Exp. Ther., 271, 91–99.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pavan Kumar, V.V., Srinivas, N.R. Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. Eur. J. Drug Metabol. Pharmacokinet. 33, 247–252 (2008). https://doi.org/10.1007/BF03190880
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190880